Oral Arguments Preview: Teva v. Amneal Tests Scope of Orange Book Device Patent ListingsThe Federal Circuit's decision in Teva v. Amneal could redefine pharmaceutical patent listing requirements under the Hatch-Waxman Act.The ruling may impact how device patents related to drugs are treated in the FDA's Orange Book.
Amarin Seeks En Banc Review in Skinny Label InducementHikma's petition challenges the Federal Circuit's skinny label jurisprudence, with implications for patent protections in the pharmaceutical sector.